Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma
Clinical trial NCT07518602 · RECRUITING
Trial details
- NCT number
- NCT07518602
- Sponsor
- Sun Yat-sen University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-27
- Primary completion
- 2028-03-27
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.